Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $18.00.
A number of research analysts recently issued reports on the stock. Citigroup decreased their price objective on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, March 13th. Cantor Fitzgerald assumed coverage on Candel Therapeutics in a research note on Monday, April 20th. They set an “overweight” rating for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Candel Therapeutics in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Monday, April 20th. Finally, Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th.
Read Our Latest Report on CADL
Candel Therapeutics Trading Down 0.5%
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.16. On average, analysts forecast that Candel Therapeutics will post -0.97 earnings per share for the current fiscal year.
Insider Activity
In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.02, for a total transaction of $70,140.00. Following the completion of the transaction, the chief technology officer owned 83,865 shares of the company’s stock, valued at approximately $840,327.30. The trade was a 7.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Francesca Barone sold 23,447 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.06, for a total value of $235,876.82. Following the transaction, the insider directly owned 77,362 shares of the company’s stock, valued at approximately $778,261.72. The trade was a 23.26% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 14.30% of the company’s stock.
Institutional Investors Weigh In On Candel Therapeutics
A number of hedge funds have recently made changes to their positions in CADL. Vanguard Group Inc. grew its holdings in shares of Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after purchasing an additional 219,563 shares during the last quarter. Geode Capital Management LLC lifted its stake in Candel Therapeutics by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 977,512 shares of the company’s stock valued at $5,524,000 after purchasing an additional 49,315 shares during the last quarter. Halter Ferguson Financial Inc. lifted its stake in Candel Therapeutics by 20.9% in the 1st quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock valued at $4,430,000 after purchasing an additional 155,996 shares during the last quarter. State Street Corp boosted its position in Candel Therapeutics by 15.0% in the fourth quarter. State Street Corp now owns 792,218 shares of the company’s stock valued at $4,476,000 after buying an additional 103,452 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in Candel Therapeutics in the first quarter valued at approximately $845,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.
Candel Therapeutics Company Profile
Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.
Featured Articles
- Five stocks we like better than Candel Therapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
